GlassScriptPhysician profile
Michael Caid Evans
NPI 1790188910
$4,007.83
in general payments reported to CMS, 2019-2025
48 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $399 · 2022: $844 · 2023: $694 · 2024: $1,012 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.76 | 2021-2025 | |
| Pfizer INC. | $220.61 | 2023-2025 | |
| Lilly USA, LLC | $195.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $189.87 | 2021-2024 | Spravato |
| Glaxosmithkline, LLC. | $163.08 | 2022-2025 | Trelegy Ellipta, Bexsero |
| Novo Nordisk INC | $157.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $156.34 | 2021-2024 | Otezla, Repatha, Prolia |
| Axsome Therapeutics, INC. | $145.38 | 2024-2025 | Auvelity, Sunosi |
| Astrazeneca Pharmaceuticals LP | $137.46 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.97 | 2024-2025 | Caplyta |
| Progenics Pharmaceuticals, INC. | $106.02 | 2023-2024 | Pylarify |
| Harmony Biosciences LLC | $103.47 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $101.00 | 2023 | Ingrezza |
| Dynavax Technologies Corporation | $99.81 | 2021-2025 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.81 | 2024-2025 | Jardiance, Synjardy |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.